



PartnerDEX

PartnerDEX AT A GLANCE

- › Full-service customizable discovery partnership
- › Access to X-Chem's complete DEL library collection
- › Target-based exclusivity for the duration of the project
- › Exclusive license to confirmed hit compounds
- › Experienced program management and oversight
- › Leverage the know-how and expertise of DEL pioneers

Full-Service Discovery Partnership

Many X-Chem partners value the depth and security of a full-service discovery relationship. PartnerDEX provides access to our most expansive DEL libraries, a chemical resource that consists of over 200 billion molecules and has generated over 85 drug discovery licenses. And when you choose PartnerDEX, the world's leading DEL experts will be standing beside you every step of the way.

Dedicated Support From DEL Technology Pioneers

Under the PartnerDEX model, X-Chem scientists work closely with our partners, helping with reagent design, generation and qualification, as well as with designing the optimal selection campaign. We translate your disease hypothesis into a powerful and informative selection experiment, calibrated to deliver the highest quality chemical matter for your project.

Following the DEL selection, X-Chem applies its industry-leading informatics platform to analyze the incredible volume of output data. This in-depth analysis enables X-Chem scientists to accelerate the design and synthesis of hit compounds. X-Chem and the client collaborate to demonstrate relevant biological characteristics and further confirm tractability and structure-activity relationships (SAR).

Ongoing Possibilities With PartnerDEX

Partners access the full power of X-Chem's DEL discovery platform. Once we discover your hits compounds, you can continue to benefit from X-Chem's small molecule discovery expertise. Our demonstrated track record in hit-to-lead and lead optimization allows a seamless transition from screening into medicinal chemistry, all informed by the powerful breadth of SAR data delivered by the DEL platform.

When you look for the **most powerful small molecule discovery platform**, top scientific expertise and a trusted partner who aligns with your goals, choose PartnerDEX by X-Chem.

Why Choose PartnerDEX?

PartnerDEX is an industry-leading, customized solution for the identification of quality hits for your priority target. Your therapeutic expertise, combined with X-Chem's breakthrough technology, equals unmatched potential.

Benefit From an Industry-Leading Partnership Model

- › Dedicated alliance management support
- › Experienced scientific oversight to guide research program
- › Proven track record of success

DEL Expertise From Reagent Design to Hit Identification and Beyond

- › DEL experts focused on your target and program goals
- › Experts in qualifying reagents to optimize DEL screening success
- › Experts in DEL selection science – latest screening methods and techniques
- › Experts in DEL data analysis – proprietary tools to identify qualified hits and leads

Advanced PartnerDEX Library Set Used for Screens

- › 10+ years of DEL design concepts
- › Our most expansive libraries that focus on drug-like molecular properties
- › Macrocycle and covalent compound libraries to address difficult biology
- › Hundreds of billions of compounds and growing

X-Chem is the partner you need to unlock exponential possibilities in your small molecule drug discovery.

Find Your Next Candidate With X-Chem

ABOUT X-CHEM

X-Chem, Inc. is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. In-house lead optimization services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimization through candidate identification.